Date: 2015-10-07
Type of information: Results
phase: preclinical
Announcement: results
Company: Dyadic (USA - FL) Sanofi Pasteur (France)
Product: C1 derived vaccine
Action mechanism:
Disease:
Therapeutic area: Infectious diseases - Veterinary medicine
Country:
Trial details:
Latest
news: * On October 7, 2015, Dyadic International announced it has received the test results from the mice trials in its research
program with Sanofi Pasteur. The data generated by Sanofi Pasteur indicates that the C1 produced antigen generated an equal, or better, immune response in mice than the industry standard antigen. “We are very encouraged by these results and remain optimistic as to the potential benefits our C1 technology can bring to the biopharmaceutical industry. We believe our C1 Expression System has the potential to aid in the discovery, development and manufacture of new, better and more affordable human
and animal vaccines, antibodies, biosimilars and other therapeutic proteins,” said Dyadic’s founder & CEO, Mark Emalfarb. “Our expansion into biopharmaceutical’s is taking shape. With the promising Sanofi results and our participation in the EU funded Zoonoses Anticipation and Preparedness Initiative or ZAPI, which was launched earlier this year, we expect to further develop our capabilities and establish our C1 Technology as a competitive manufacturing platform for use in producing novel, and low cost vaccines, biosimilars and other biologics.“
The ZAPI initiative, sponsored by the EU Horizon 2020 program, brings together and will draw upon leading human and animal health expertise across Europe. The objective of the program is to develop an end-to-end solution for the rapid development, production, regulatory approval and launch of vaccine products to combat epidemic infectious diseases in animals that have the potential to effect the human population. Led by Merial, Sanofi’s animal health arm, participants within ZAPI include experts from
regulatory agencies, academia and industry including AstraZeneca, Utrecht University, University of Bonn, Leiden University and a number of small and medium enterprises (SMEs).
